JNJames C. Neil

James C. Neil

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James C. Neil has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Karen Blyth

    Cancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK

    6 shared publications
  • Ewan R. Cameron

    Molecular Oncology Laboratory, Institute of Comparative Medicine, University of Glasgow Veterinary School, Glasgow, UK

    3 shared publications
  • A Jenkins

    Molecular Oncology Laboratory, Institute of Comparative Medicine, University of Glasgow, Faculty of Veterinary Medicine, Bearsden, Glasgow G61 1QH, Scotland

    2 shared publications
  • A Kilbey

    Molecular Oncology Laboratory, Institute of Comparative Medicine, University of Glasgow, Faculty of Veterinary Medicine, Bearsden, Glasgow G61 1QH, Scotland

    2 shared publications
  • A Terry

    Molecular Oncology Laboratory, Institute of Comparative Medicine, University of Glasgow, Faculty of Veterinary Medicine, Bearsden, Glasgow G61 1QH, Scotland

    2 shared publications
  • E Cameron

    Molecular Oncology Laboratory, Institute of Comparative Medicine, University of Glasgow, Faculty of Veterinary Medicine, Bearsden, Glasgow G61 1QH, Scotland

    2 shared publications

Latest Publications

  • Open Access

    A Novel Model of SCID-X1 Reconstitution Reveals Predisposition to Retrovirus-induced Lymphoma but No Evidence of γC Gene Oncogenicity

    by Linda Scobie, Ralph D Hector, Louise Grant, Margaret Bell, Anne A Nielsen, Sharon Meikle, Adrain Philbey, Adrain J Thrasher, Ewan R Cameron, Karen Blyth, et al.


  • Open Access

    RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress

    by K Wolyniec, S Wotton, A Kilbey, A Jenkins, A Terry, G Peters, C Stocking, E Cameron, J C Neil

    A role for the RUNX genes in cancer fail-safe processes has been suggested by their induction of senescence-like growth arrest in primary murine fibroblasts and the failure of RAS-induced senescence in Runx2-deficient cells. We now show that RUNX1 induces senescence in human primary fibroblasts. High-affinity DNA binding is necessary but not sufficient, as shown by the functional attenuation of the truncated RUNX1/AML1a isoform and the TEL-RUNX1 fusion oncoprotein. However, a similar phenotype was potently induced by the RUNX1-ETO (AML1-ETO) oncoprotein, despite its dominant-negative potential. A detailed comparison of H-RASV12, RUNX1 and RUNX1-ETO senescent phenotypes showed that the RUNX effectors induce earlier growth stasis with only low levels of DNA damage signaling and a lack of chromatin condensation, a marker of irreversible growth arrest. In human fibroblasts, all effectors induced p53 in the absence of detectable p14Arf, whereas only RUNX1-ETO induced senescence in p16Ink4a-null cells. Correlation was noted between induction of p53, reactive oxygen species and phospho-p38, whereas p38MAPK inhibition rescued cell growth markedly. These findings indicate a role for replication-independent pathways in RUNX and RUNX1-ETO senescence, and show that the context-specific oncogenic activity of RUNX1 fusion proteins is mirrored in their distinctive interactions with fail-safe responses.


  • Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival

    by S Wotton, A Terry, A Kilbey, A Jenkins, P Herzyk, E Cameron, J C Neil

    The Runx genes are important in development and cancer, where they can act either as oncogenes or tumour suppressors. We compared the effects of ectopic Runx expression in established fibroblasts, where all three genes produce an indistinguishable phenotype entailing epithelioid morphology and increased cell survival under stress conditions. Gene array analysis revealed a strongly overlapping transcriptional signature, with no examples of opposing regulation of the same target gene. A common set of 50 highly regulated genes was identified after further filtering on regulation by inducible RUNX1-ER. This set revealed a strong bias toward genes with annotated roles in cancer and development, and a preponderance of targets encoding extracellular or surface proteins, reflecting the marked effects of Runx on cell adhesion. Furthermore, in silico prediction of resistance to glucocorticoid growth inhibition was confirmed in fibroblasts and lymphoid cells expressing ectopic Runx. The effects of fibroblast expression of common RUNX1 fusion oncoproteins (RUNX1-ETO, TEL-RUNX1 and CBFB-MYH11) were also tested. Although two direct Runx activation target genes were repressed (Ncam1 and Rgc32), the fusion proteins appeared to disrupt the regulation of downregulated targets (Cebpd, Id2 and Rgs2) rather than impose constitutive repression. These results elucidate the oncogenic potential of the Runx family and reveal novel targets for therapeutic inhibition.


  • Insertional Mutagenesis Reveals Progression Genes and Checkpoints in MYC/Runx2 Lymphomas

    by Monica Stewart, Nancy Mackay, Linda Hanlon, Karen Blyth, Linda Scobie, Ewan Cameron, James C. Neil

    In this study, we have exploited the power of insertional mutagenesis to elucidate tumor progression pathways in mice carrying two oncogenes (MYC/Runx2) that collaborate to drive early lymphoma development. Neonatal infection of these mice with Moloney murine leukemia virus resulted in accelerated tumor onset with associated increases in clonal complexity and lymphoid dissemination. Large-scale analysis of retroviral integration sites in these tumors revealed a profound bias towards a narrow range of target genes, including Jdp2 (Jundm2), D cyclin, and Pim family genes. Remarkably, direct PCR analysis of integration hotspots revealed that every progressing tumor consisted of multiple clones harboring hits at these loci, giving access to large numbers of independent insertion events and uncovering the contrasting mutagenic mechanisms operating at each target gene. Direct PCR analysis showed that high-frequency targeting occurs only in the tumor environment in vivo and is specific for the progression gene set. These results indicate that early lymphomas in MYC/Runx2 mice remain dependent on exogenous growth signals, and that progression can be achieved by constitutive activation of pathways converging on a cell cycle checkpoint that acts as the major rate-limiting step for lymphoma outgrowth. [Cancer Res 2007;67(11):5126–33]


  • The runx genes: gain or loss of function in cancer

    by Karen Blyth, Ewan R. Cameron, James C. Neil

    The RUNX genes encode transcription factors that bind DNA as components of the core-binding factor (CBF) complex, in partnership with the CBFβ cofactor. This complex activates and represses transcription of key regulators of growth, survival and differentiation pathways. The mouse RUNX genes are closely related and are essential for haematopoiesis, osteogenesis and neurogenesis, but are also important for other developmental processes. The RUNX genes have been found to function as both tumour suppressors and dominant oncogenes in a context-dependent manner. RUNX1 is a frequent target of chromosomal translocation in distinct subtypes of human leukaemia: RUNX1–ETO occurs in 10–20% of acute myeloid leukaemias and TEL–RUNX1 in 20–25% of childhood acute lymphoid leukaemias. Functional disruption of RUNX1 by chromosomal translocation and somatic point mutation occurs commonly in myeloid leukaemia. RUNX1 mutations have also been linked with familial predisposition to acute leukaemia. Hypermethylation of RUNX3 has been found in several human epithelial cancers and loss of Runx3 predisposes knockout mice to gastric hyperplasia, indicating a tumour-suppressor-like role for this gene. All three RUNX genes are targets for retroviral insertional activation in mouse lymphoma models, and transgenic mice expressing full-length Runx2 develop T-cell lymphoma, confirming the oncogenic potential of this gene family. Amplification of RUNX1 has been linked with poor prognosis in childhood B-cell leukaemia, while RUNX2 expression has been implicated in bone metastasis. RUNX proteins are central to pathways regulating cell growth and differentiation. Of particular note are the interactions of RUNX activities with the transforming growth factor-β pathway.


    • 15 December 2002
      • Vol. 62  (24) , 7175-80

    Feline immunodeficiency virus integration in B-cell lymphoma identifies a candidate tumor suppressor gene on human chromosome 15q15.

    by Julia Beatty, Anne Terry, Julie MacDonald, Elizabeth Gault, Stan Cevario, Stephen J O'Brien, Ewan Cameron, James C Neil

    Infection with immunosuppressive lentiviruses is associated with increased cancer risk,but most studies have implicated indirect mechanisms as the tumor cells generally lack integrated viral sequences. An exception wasfound in a B-cell lymphoma (Q254) where the tumor cells contained a single integrated feline immunodeficiency virus genome. Additional analysis now indicates that feline immunodeficiency virus integration in lymphoma Q254 resulted in promoter insertion and truncation of a conserved gene on feline chromosome B3, whereas the unaffected allele of the gene appeared to be transcriptionally down-regulated. The orthologous human gene (FLJ12973), is expressed ubiquitously and encodes a WD-repeat protein with structural similarity to DDB2, the small subunit of the xeroderma pigmentosum XP-E complex. Moreover, the gene is located within a region of frequent tumor-specific deletions on chromosome 15q15. These observations demonstrate the direct mutagenic potential of the lentiviruses and identify a new candidate tumor suppressor gene.


    • 15 December 2002
      • Vol. 62  (24) , 7181-5

    Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma.

    by Sandy Wotton, Monica Stewart, Karen Blyth, Francois Vaillant, Anna Kilbey, James C Neil, Ewan R Cameron

    The RUNX1/AML1 gene is a frequent target for chromosomal translocations in human leukemia. The biological properties of the resulting fusion products and the finding that haploinsufficiency increases the risk of developing leukemia (W-J. Song et al., Nat. Genet., 23: 166-175, 1999; M. Osata et al., Blood, 93: 1817-1824, 1999) have led to the widely held view that RUNX1 loss-of-function is a key event. However, we now report that the gene is a target for insertional mutagenesis in T-cell lymphomas of mice carrying a MYC oncogene, where promoter insertion results in overexpression without affecting the integrity of the coding sequence. Moreover, Runx1 haploinsufficiency does not accelerate lymphoma development in MYC/Runx2 transgenic or murine leukemia virus-infected mice. These findings reveal that the Runx1 gene can also act as a dominant oncogene and suggest that the involvement of the Runx gene family in human leukemia may be more widespread and complex than previously realized.


  • Open Access

    Retroviral insertion sites and cancer: Fountain of all knowledge?

    by James C Neil, Ewan R Cameron


  • Selection for Loss of p53 Function in T-Cell Lymphomagenesis Is Alleviated by Moloney Murine Leukemia Virus Infection in myc Transgenic Mice

    by Euan W. Baxter, Karen Blyth, Ewan R. Cameron, James C. Neil

    Thymic lymphomas induced by Moloney murine leukemia virus (MMLV) have provided many examples of oncogene activation, but the role of tumor suppressor pathways in these tumors is less clear. These tumors display little evidence of loss of heterozygosity, and MMLV is only weakly synergistic with the Trp53 null genotype, suggesting that viral lymphomagenesis involves mechanisms which do not require mutational loss of Trp53 function. To explore this relationship in greater depth, we infected CD2- myc transgenic mice with MMLV and examined the role of Trp53 in the genesis of these tumors. Most (19 of 27) of the tumors from MMLV-infected, CD2- myc Trp53 +/− mice retained the wild-type Trp53 allele in vivo while tumors of uninfected CD2- myc Trp53 +/− mice invariably showed allele loss from a significant fraction of primary tumor cells. The functional integrity of the Trp53 gene in these tumors was indicated by ongoing allele loss or selection for mutational stabilization during in vitro propagation and by the radiosensitivity of selected Trp53 +/− tumor cell lines. An inverse correlation was noted between retention of the wild-type Trp53 allele and expression of p19 ARF , providing further evidence of negative-feedback control of the latter by p53. However, expression of p19 ARF does not appear to be counterselected in the absence of p53, and its integrity in Trp53 +/− tumors was indicated by its transcriptional upregulation on Trp53 wild-type allele loss in vitro in selected tumor cell lines. The role of MMLV was investigated further by analysis of proviral insertion sites in tumors of CD2- myc transgenic mice sorted for Trp53 genotype. A proportion of tumors showed insertions at Runx2 , an oncogene which has been shown to collaborate independently with CD2- myc and with the Trp53 null genotype, and at a novel common integration site ( ptl-1 ) on chromosome 8. Genotypic analysis of the panel of tumors suggested that neither of these integrations is functionally redundant with loss of p53, but it appears that the combination of the MMLV oncogenic program with the CD2- myc oncogene relegates p53 loss to a late step in tumor progression or in vitro culture. While the means by which these tumors preempt the p53 tumor suppressor response remains to be established, this study provides further evidence that irreversible inactivation of this pathway is not a prerequisite for tumor development in vivo.